These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 25531195)

  • 21. Everolimus for the treatment of advanced renal cell carcinoma.
    Amato R
    Expert Opin Pharmacother; 2011 May; 12(7):1143-55. PubMed ID: 21470068
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Incidence and risk of high-grade stomatitis with mTOR inhibitors in cancer patients.
    Shameem R; Lacouture M; Wu S
    Cancer Invest; 2015 Mar; 33(3):70-7. PubMed ID: 25635371
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Incidence and risk of rash to mTOR inhibitors in cancer patients--a meta-analysis of randomized controlled trials.
    Shameem R; Lacouture M; Wu S
    Acta Oncol; 2015 Jan; 54(1):124-32. PubMed ID: 24914484
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Everolimus: a new hope for patients with breast cancer.
    Sendur MA; Zengin N; Aksoy S; Altundag K
    Curr Med Res Opin; 2014 Jan; 30(1):75-87. PubMed ID: 24050600
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Everolimus: a proliferation signal inhibitor with clinical applications in organ transplantation, oncology, and cardiology.
    Gabardi S; Baroletti SA
    Pharmacotherapy; 2010 Oct; 30(10):1044-56. PubMed ID: 20874042
    [TBL] [Abstract][Full Text] [Related]  

  • 26. mTOR, p70S6K, AKT, and ERK1/2 levels predict sensitivity to mTOR and PI3K/mTOR inhibitors in human bronchial carcinoids.
    Gagliano T; Bellio M; Gentilin E; Molè D; Tagliati F; Schiavon M; Cavallesco NG; Andriolo LG; Ambrosio MR; Rea F; Degli Uberti E; Zatelli MC
    Endocr Relat Cancer; 2013 Aug; 20(4):463-75. PubMed ID: 23653462
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Renal function preservation with the mTOR inhibitor, Everolimus, after lung transplant.
    Schneer S; Kramer MR; Fox B; Rusanov V; Fruchter O; Rosengarten D; Bakal I; Medalion B; Raviv Y
    Clin Transplant; 2014 Jun; 28(6):662-8. PubMed ID: 24738962
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Paronychia and pyogenic granuloma induced by new anticancer mTOR inhibitors.
    Sibaud V; Dalenc F; Mourey L; Chevreau C
    Acta Derm Venereol; 2011 Sep; 91(5):584-5. PubMed ID: 21667012
    [No Abstract]   [Full Text] [Related]  

  • 29. Everolimus: an mTOR inhibitor for the treatment of tuberous sclerosis.
    Franz DN
    Expert Rev Anticancer Ther; 2011 Aug; 11(8):1181-92. PubMed ID: 21916571
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Everolimus: side effect profile and management of toxicities in breast cancer.
    Paplomata E; Zelnak A; O'Regan R
    Breast Cancer Res Treat; 2013 Aug; 140(3):453-62. PubMed ID: 23907751
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Everolimus.
    Hasskarl J
    Recent Results Cancer Res; 2014; 201():373-92. PubMed ID: 24756805
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Everolimus: a new mammalian target of rapamycin inhibitor for the treatment of advanced renal cell carcinoma.
    Grgic T; Mis L; Hammond JM
    Ann Pharmacother; 2011 Jan; 45(1):78-83. PubMed ID: 21177421
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Noninfectious pneumonitis with the use of mTOR inhibitors in breast cancer.
    Peddi PF; Shatsky RA; Hurvitz SA
    Cancer Treat Rev; 2014 Mar; 40(2):320-6. PubMed ID: 24011786
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Safety considerations of mammalian target of rapamycin inhibitors in tuberous sclerosis complex and renal transplantation.
    Somers MJ; Paul E
    J Clin Pharmacol; 2015 Apr; 55(4):368-76. PubMed ID: 25402866
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Everolimus: a guide to its use in liver transplantation.
    Keating GM; Lyseng-Williamson KA
    BioDrugs; 2013 Aug; 27(4):407-11. PubMed ID: 23696253
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sirolimus and everolimus in kidney transplantation.
    Moes DJ; Guchelaar HJ; de Fijter JW
    Drug Discov Today; 2015 Oct; 20(10):1243-9. PubMed ID: 26050578
    [TBL] [Abstract][Full Text] [Related]  

  • 37. mTOR Inhibition and Cardiovascular Diseases: Dyslipidemia and Atherosclerosis.
    Kurdi A; Martinet W; De Meyer GRY
    Transplantation; 2018 Feb; 102(2S Suppl 1):S44-S46. PubMed ID: 28230638
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Can patients maintain their use of everolimus until lung transplantation?
    Costa AN; Baldi BG; de Oliveira Braga Teixeira RH; Samano MN; de Carvalho CR
    Transplantation; 2015 Jun; 99(6):e42-3. PubMed ID: 26035277
    [No Abstract]   [Full Text] [Related]  

  • 39. Treatment with everolimus is associated with a procoagulant state.
    Baas MC; Gerdes VE; Ten Berge IJ; Heutinck KM; Florquin S; Meijers JC; Bemelman FJ
    Thromb Res; 2013 Aug; 132(2):307-11. PubMed ID: 23906938
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Common toxicities of mammalian target of rapamycin inhibitors.
    Soefje SA; Karnad A; Brenner AJ
    Target Oncol; 2011 Jun; 6(2):125-9. PubMed ID: 21499766
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.